Catalog No.
RHN64602
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IF: 1:50-1:200, WB: 1:1000-1:2000
Target
Uridine diphosphate-N-acetylglucosamine-2-epimerase, Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, UDP-GlcNAc-2-epimerase, UDP-GlcNAc-2-epimerase/ManAc kinase, GLCNE, GNE, ManAc kinase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9Y223
Applications
IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R2P64
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial., PMID:40367619
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial., PMID:40293644
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting., PMID:40288116
Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies., PMID:40284495
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities., PMID:40196986
Central Nervous System Metastases in Breast Cancer., PMID:39786689
Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis., PMID:39574495
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus., PMID:39511302
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)., PMID:39375745
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer., PMID:39226397
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival., PMID:39211994
What is in the Myopathy Literature?, PMID:39163158
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)., PMID:38967884
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial., PMID:38796287
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO., PMID:38689174
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma., PMID:38653033
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial., PMID:38514306
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study., PMID:37938495
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial., PMID:37919269
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update., PMID:37827694
Proteomic analysis of stimulated saliva in gastroesophageal reflux disease patients with and without erosive tooth wear: Observational study., PMID:37797812
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab., PMID:37562696
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor., PMID:37125593
Multiplex Assay for Simultaneous Detection of Antibodies against Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein and Glycoproteins in Ruminants., PMID:36815788
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial., PMID:36681013
HER2-Low Breast Cancer: Where Are We?, PMID:36590146
Treatment of Refractory Metastatic Renal Cell Carcinoma., PMID:36291789
Optic neuritis in lung adenocarcinoma: A challenging diagnosis., PMID:36274550
In vivo and in vitro genome editing to explore GNE functions., PMID:36237634
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study., PMID:36050448
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis., PMID:35867203
Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine., PMID:35572397
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study., PMID:35358443
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial., PMID:35313167
How we treat patients with metastatic HER2-positive breast cancer., PMID:34995893
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study., PMID:34800178
Visualizing Muscle Sialic Acid Expression in the GNED207VTgGne-/- Cmah-/- Model of GNE Myopathy: A Comparison of Dietary and Gene Therapy Approaches., PMID:34511508
The GNE-KLH anti-cocaine vaccine protects dams and offspring from cocaine-induced effects during the prenatal and lactating periods., PMID:34381172
Targeting Cancer Metabolism Breaks Radioresistance by Impairing the Stress Response., PMID:34359663
The Exciting New Field of HER2-Low Breast Cancer Treatment., PMID:33804398
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial., PMID:33388492
Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use., PMID:33253224
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial., PMID:33246931
Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?, PMID:33214229
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial., PMID:33154022
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial., PMID:33109233
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial., PMID:32661118
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations., PMID:32616076
HER2-positive advanced breast cancer treatment in 2020., PMID:32534233
For research use only. Not for human or drug use.
